NL-OMON43305
Not Yet Recruiting
N/A
Discovery of non-invasive biomarkers for immune-mediated liver diseases; AIH, DILI, NAFL and NASH. - Discovery of biomarkers for immune-mediated liver diseases.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vrije Universiteit Medisch Centrum
- Enrollment
- 100
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •\* Indication for a biopsy for the diagnosis or monitoring of; AIH, DILI, NAFL or NASH
- •\* Eligible for liver biopsy
- •\* \* 18 years old
- •\* Provide informed consent
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •\* Contraindication for liver biopsy, determined by the clinician.
- •\* Current infectious disease.
- •\* Clinically relevant cardiovascular, pulmonary, or renal disease.
- •\* Medications with possible immune\-modulating effects (e.g., steroids).
- •\* History of alcohol or drug abuse.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
N/A
Discovery of biomarkers for immune-mediated liver disease.autoimmune hepatitis, drug-induced liver injury, non-alcoholic fatty liver disease and non-alcoholic steatohepatitisNL-OMON24228Investigator initiated study, funded by the Vrije Universiteit, University Medical Center
Recruiting
N/A
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
Active, Not Recruiting
N/A
Probiotics and its effect on stress and sleepHealth Condition 1: R69- Illness, unspecifiedHealth Condition 2: null- patients admitted in hospital and posted for elective surgeriesCTRI/2018/03/012276RGUHS bengaluru
Completed
N/A
Immunological monitoring and assessment of biomarkers predictive of clinical response to first-line treatment with bosutinib or imatinib in chronic phase chronic myeloid leukemiaChronic myeloid leukemiaCML10024324NL-OMON42791Vrije Universiteit Medisch Centrum5
Not Yet Recruiting
N/A
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000047162Kobe University114